<DOC>
	<DOCNO>NCT01583036</DOCNO>
	<brief_summary>An interaction study assess effect ezogabine/retigabine main metabolite NAMR pharmacokinetics digoxin healthy volunteer</brief_summary>
	<brief_title>An Open-label , Single-centre Study Evaluating Pharmacokinetics Digoxin Alone When Administered Various Doses Ezogabine/Retigabine Healthy Adults . The Pharmacokinetics Ezogabine/Retigabine N-acetyl Metabolite Ezogabine/Retigabine ( NAMR ) Will Also Assessed</brief_title>
	<detailed_description>This open-label , single-centre study evaluate pharmacokinetics single-dose digoxin alone administer various titration dos ezogabine/retigabine healthy adult subject . The pharmacokinetics ezogabine/retigabine n-acetyl metabolite ezogabine/retigabine ( NAMR ) also assess .</detailed_description>
	<mesh_term>Digoxin</mesh_term>
	<mesh_term>Ezogabine</mesh_term>
	<criteria>Male female 18 65 year age inclusive , time signing informed consent . Healthy determine responsible experienced physician , base medical evaluation include medical history , physical examination , laboratory test cardiac monitoring . A subject clinical abnormality laboratory parameter outside reference range population study may include Investigator GSK Medical Monitor agree find unlikely introduce additional risk factor interfere study procedure . A female subject eligible participate : Nonchildbearing potential define premenopausal female document tubal ligation hysterectomy ; postmenopausal define 12 month spontaneous amenorrhea [ questionable case blood sample simultaneous follicle stimulate hormone ( FSH ) great 40 MlU/ml estradiol le 40 pg/ml ( le 147 pmol/L ) confirmatory ] . Females hormone replacement therapy ( HRT ) whose menopausal status doubt require use one contraception method protocol wish continue HRT study . Otherwise , must discontinue HRT allow confirmation postmenopausal status prior study enrollment . For form HRT , least 24 week elapse cessation therapy blood draw ; interval depend type dosage HRT . Following confirmation postmenopausal status , resume use HRT study without use contraceptive method ; Childbearing potential agrees use one contraception method list protocol appropriate period time ( determined product label investigator ) prior start dose sufficiently minimize risk pregnancy point . Female subject must agree use contraception 1 week postlast dose ezogabine/retigabine . Male subject female partner childbearing potential must agree use one contraception method list protocol . This criterion must follow time first dose study medication least 1 week postlast dose . BMI 18 30 kg/m2 total body weight great 50 kg ( 110 lb ) . Normal creatinine clearance assess CockcroftGault Method . Subject 's aspartate aminotransferase , ALT , alkaline phosphatase , bilirubin great equal 1.5 × ULN ( isolate bilirubin great 1.5 × ULN acceptable bilirubin fractionate direct bilirubin le 35 % ) . Subject nonsmoker ( define nonsmoker last 3 month prior Screening negative cotinine test screening ) . Subject negative drug screen ( amphetamine , barbiturate , cocaine metabolite , opiate , benzodiazepine , cannabinoids ) Screening checkin Day 1 . Subject capable give write informed consent , include compliance requirement restriction list consent form . Subject positive test result hepatitis B surface antigen , positive hepatitis C virus , human immunodeficiency virus ( HIV ) 1 2 Screening Has active suicidal plan/intent active suicidal thought past 6 month . Has history suicide attempt last 2 year 1 lifetime suicide attempt . Presence proteinuria ( least ++ ) hematuria clinically significant finding urinalysis screening . Has history urinary retention risk factor urinary retention Investigator 's judgment could potentially affect subject safety . Subject history syncope , clinically significant palpitation , bradyarrhythmia tachyarrhythmia conduction abnormality ( e.g. , atrioventricular block degree , e.g. , leave bundlebranch block , right bundlebranch block ) , WolfParkinsonWhite syndrome , clinically relevant abnormality identify screen medical assessment , laboratory examination , ECG , immunogenicity test Subject 's blood pressure great equal 140/90 mm Hg heart rate great 100 beats/min Screening ; repeat blood pressure take subject 's blood pressure great equal 140/90 mm Hg result consistently great equal 140/90 mm Hg , subject exclude advised consult physician . Subject 's QTc interval great 450 m ( per ECG machine interpretation ) screening ; repeat measurement take QTc great 450 m result consistently great 450 m , subject exclude Female subject pregnant breastfeeding Subject history anaphylactic reaction drug know hypersensitivity : LANOXIN/digoxin and/or excipients , digoxinlike medication ; Ezogabine/retigabine ; History sensitivity study medication , component thereof history drug allergy , opinion investigator GSK Medical Monitor , contraindicate participation . Subject history significant cardiovascular pulmonary dysfunction prior Screening Subject fast triglyceride level great 300 mg/dL Screening Subject current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert syndrome asymptomatic gallstone ) Subject history alcohol substance abuse within last 2 year Subject donate blood excess 500 mL within 56 day prior dose intention donate month complete study Subject history gastrointestinal surgery could influence gastric emptying ( e.g. , gastrectomy , gastric bypass ) Subject history inflammatory bowel disease irritable bowel syndrome Subject receive investigational drug within 30 day prior dose study medication 5 halflives , whichever longer Subject unlikely comply study protocol and/or complete study require study procedure unlikely unable return followup visit Subject use prescription medication overthecounter medication , herbal supplement , multivitamin within 14 day prior dose study medication ( begin first dose digoxin ) ( see Section 9.2 additional detail ) Subject consume grapefruit juice , cranberry product ( juice , fruit , nutritional supplement ) , alcohol , caffeine , xanthinecontaining product within 7 day ( 5 elimination half live whichever short ) prior start dose study medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>